Fortunately, AMD300, a CXCR4 inhibitor approved by the United States Food and Drug Administration (FDA), has already been shown to disrupt tumor-stromal interactions, sensitizing cancer cells to docetaxel-based chemotherapy in prostate cancer (Domanska et al., 2012). This evidence concerns the gene CXCR4 and prostate carcinoma.